Skip to ContentSkip to Navigation
About us Practical matters How to find us R.A. (Rudolf) de Boer

Publications

Beyond the gut: Systemic levels of short-chain fatty acids are altered in patients with heart failure

Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity

Circulating bmp10 (bone morphogenic protein 10) in the assessment of congestion and pulmonary hypertension

Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure

Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: Data from PREVEND

The Role of Comorbidities and Lifestyle Factors in Disease Progression of Phospholamban Cardiomyopathy

An increase in albuminuria is associated with a higher incidence of malignancies

Association of fibrotic markers with diastolic function after STEMI

Associations of relative fat mass and BMI with all-cause mortality: Confounding effect of muscle mass

Press/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'